ImmunoGen Competitors and Similar CompaniesClear all

ImmunoGen's competitors and similar companies include ADC Therapeutics and Puma Biotechnology.

	ImmunoGen ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.	ADC Therapeutics ADC Therapeutics is a biotechnology company that develops drug conjugates for the treatment of both solid and haematological cancers.	Puma Biotechnology Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.
Founding Date	Founding Date 1981	Founding Date 2010	Founding Date 2010
Type	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development oncology	Tags Healthcare biotech drug development healthtech oncology	Tags Healthcare biotech drug development oncology pharma
Locations	Locations Waltham, US HQ	Locations Epalinges, CH HQ London, GB New Providence, US	Locations Los Angeles, US HQ
Employees	Employees 277161% increase	Employees 1162% increase	Employees 27214% decrease
Valuation ($)	Valuation ($) 8.7 b	Valuation ($) 295.9 m	Valuation ($) 136.8 m
Financial
Revenue (est.)	Revenue (est.) $108.8m (FY, 2022)	Revenue (est.) $81.4m (FY, 2025)	Revenue (est.) $228.4m (FY, 2025)
Cost of goods	Cost of goods $176k (FY, 2022)	Cost of goods $5.1m (FY, 2025)	Cost of goods $58.2m (FY, 2025)
Gross profit	Gross profit $108.6m (FY, 2022)	Gross profit $76.3m (FY, 2025)	Gross profit $170.2m (FY, 2025)
Net income	Net income ($222.9m) (FY, 2022)	Net income ($142.6m) (FY, 2025)	Net income N/A
Funding
Total funding raised	Total funding raised $ 56m	Total funding raised $ 526m	Total funding raised $ 172m